Sinopia Biosciences is a San Diego based biotechnology company leveraging a proprietary AI/ML drug discovery platform to identify novel therapeutics in neurology, oncology, and genetic diseases. Sinopia's platform has successfully identified multiple therapeutic opportunities, including a first-in-class small molecule for Parkinson's disease and levodopa-induced dyskinesia (PD/LID). Sinopia is currently advancing its PD/LID program through IND-enabling studies with financial support from the National Institutes of Health and The Michael J. Fox Foundation and plans to initiate Phase 1a/b studies in Q1, 2025. Sinopia has also identified a novel target for chemo/radiation-induced oral mucositis and is currently applying its data-driven approach in oncology and genetic diseases.